Extracellular fluid volume expansion is nearly universal in patients with chronic kidney disease. Such volume expansion often overlaps with the syndrome of heart failure with preserved ejection fraction, which can not only lead to symptoms, but can also lead to further organ damage. Unique treatment challenges are present in this patient population, including low glomerular filtration, which limits sodium chloride filtration, intrinsic tubule predisposition to sodium chloride retention, and proteinuria. Additionally, pharmacokinetic considerations alter the disposition of diuretics in patients with chronic kidney disease and nephrotic syndrome. Maintaining extracellular fluid volume near to normal is often necessary for hypertension treatment in this population, but it may also help prevent progressive cardiovascular and renal damage. Although powerful diuretics can often accomplish this goal, this often comes at a cost of competing side effects. An approach to reduce extracellular fluid volume while avoiding side effects, therefore, requires a nuanced yet aggressive therapeutic approach.